ImmunityBio, Inc. – NASDAQ:IBRX
ImmunityBio stock price today
$2.29
-0.49
-17.63%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
ImmunityBio stock price monthly change
-58.01%
month
ImmunityBio stock price quarterly change
-58.01%
quarter
ImmunityBio stock price yearly change
-46.44%
year
ImmunityBio key metrics
Market Cap | 1.84B |
Enterprise value | 1.23B |
P/E | -1.45 |
EV/Sales | 5145.74 |
EV/EBITDA | -3.68 |
Price/Sales | 2566.02 |
Price/Book | -1.37 |
PEG ratio | 0.08 |
EPS | -1.06 |
Revenue | 302K |
EBITDA | -341.6M |
Income | -600.96M |
Revenue Q/Q | -88.88% |
Revenue Y/Y | -48.46% |
Profit margin | -173569.58% |
Oper. margin | -146090.42% |
Gross margin | 0% |
EBIT margin | -146090.42% |
EBITDA margin | -113112.58% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmunityBio stock price history
ImmunityBio stock forecast
ImmunityBio financial statements
| Jun 2023 | 41K | -137.87M | -336290.24% |
|---|---|---|---|
| Sep 2023 | 82K | -95.58M | -116563.41% |
| Dec 2023 | 139K | -233.39M | -167907.91% |
| Mar 2024 | 40K | -134.10M | -335272.5% |
| Mar 2024 | 40K | -134.10M | -335272.5% |
|---|---|---|---|
| Sep 2025 | 70.02M | -60.37M | -86.22% |
| Oct 2025 | 70.02M | -60.55M | -86.48% |
| Dec 2025 | 86.49M | -53.82M | -62.23% |
Analysts Price target
Financials & Ratios estimates
| 2023-03-01 | -0.33137 | -0.27 |
|---|
| Jun 2023 | 291227000 | 936.41M | 321.54% |
|---|---|---|---|
| Sep 2023 | 432419000 | 843.06M | 194.96% |
| Dec 2023 | 504452000 | 1.09B | 216.15% |
| Mar 2024 | 400679000 | 1.09B | 272.45% |
| Jun 2023 | -79.77M | -8.60M | 43.41M |
|---|---|---|---|
| Sep 2023 | -87.40M | -15.63M | 237.50M |
| Dec 2023 | -115.27M | 2.24M | 200.53M |
| Mar 2024 | -106.98M | -35.62M | 10.22M |
ImmunityBio alternative data
| Aug 2023 | 703 |
|---|---|
| Sep 2023 | 683 |
| Oct 2023 | 683 |
| Nov 2023 | 683 |
| Dec 2023 | 670 |
| Jan 2024 | 670 |
| Feb 2024 | 670 |
| Mar 2024 | 628 |
| Apr 2024 | 628 |
| May 2024 | 628 |
| Jun 2024 | 628 |
| Jul 2024 | 628 |
ImmunityBio other data
7.95%
-0.37%
of IBRX is owned by hedge funds
111
-14
31.64M
-1.46M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 0 |
| Jun 2023 | 103915 | 0 |
| Sep 2023 | 0 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LAUER REGAN J officer: Chief Accounting Officer | Common Stock | 21,031 | N/A | N/A | ||
Option | LAUER REGAN J officer: Chief Accounting Officer | Restricted Stock Units | 21,031 | N/A | N/A | ||
Option | ADCOCK RICHARD director, officer: CEO & Presid.. | Common Stock | 83,334 | N/A | N/A | ||
Option | ADCOCK RICHARD director, officer: CEO & Presid.. | Restricted Stock Units | 83,334 | N/A | N/A | ||
Option | SIMON BARRY J. director | Common Stock | 57,200 | N/A | N/A | ||
Option | SIMON BARRY J. director | Restricted Stock Units | 57,200 | N/A | N/A | ||
Option | SACHS DAVID C. officer: Chief Fi.. | Common Stock | 70,745 | N/A | N/A | ||
Option | SACHS DAVID C. officer: Chief Fi.. | Restricted Stock Units | 70,745 | N/A | N/A | ||
Option | LAUER REGAN J officer: Chief Accounting Officer | Common Stock | 32,872 | N/A | N/A | ||
Option | LAUER REGAN J officer: Chief Accounting Officer | Restricted Stock Units | 32,872 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Mr. David C. Sachs (1978) Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | $567,400 |
Dr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc. (1953) Executive Chairman | $362,630 |
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
ImmunityBio: Forging A New Plan After Recent $100 Million Offering
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
ImmunityBio: Anktiva's Launch Demands A Reassessment
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
-
What's the price of ImmunityBio stock today?
One share of ImmunityBio stock can currently be purchased for approximately $2.29.
-
When is ImmunityBio's next earnings date?
Unfortunately, ImmunityBio's (IBRX) next earnings date is currently unknown.
-
Does ImmunityBio pay dividends?
No, ImmunityBio does not pay dividends.
-
How much money does ImmunityBio make?
ImmunityBio has a market capitalization of 1.84B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 159.17% to 622K US dollars. ImmunityBio made a loss 583.2M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
-
What is ImmunityBio's stock symbol?
ImmunityBio, Inc. is traded on the NASDAQ under the ticker symbol "IBRX".
-
What is ImmunityBio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ImmunityBio?
Shares of ImmunityBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ImmunityBio's key executives?
ImmunityBio's management team includes the following people:
- Mr. David C. Sachs Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer(age: 47, pay: $567,400)
- Dr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc. Executive Chairman(age: 72, pay: $362,630)
-
How many employees does ImmunityBio have?
As Jul 2024, ImmunityBio employs 628 workers.
-
When ImmunityBio went public?
ImmunityBio, Inc. is publicly traded company for more then 10 years since IPO on 28 Jul 2015.
-
What is ImmunityBio's official website?
The official website for ImmunityBio is immunitybio.com.
-
Where are ImmunityBio's headquarters?
ImmunityBio is headquartered at 3530 John Hopkins Court, San Diego, CA.
-
How can i contact ImmunityBio?
ImmunityBio's mailing address is 3530 John Hopkins Court, San Diego, CA and company can be reached via phone at 858 633 0300.
ImmunityBio company profile:
ImmunityBio, Inc.
immunitybio.comExchange:
NASDAQ
Full time employees:
672
Industry:
Biotechnology
Sector:
Healthcare
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
3530 John Hopkins Court
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001326110
ISIN: US45256X1037
CUSIP: 45256X103
